Skip to Content

Empliciti Side Effects

Generic Name: elotuzumab

Note: This document contains side effect information about elotuzumab. Some of the dosage forms listed on this page may not apply to the brand name Empliciti.

In Summary

More frequent side effects include: fever. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to elotuzumab: intravenous powder for solution

Along with its needed effects, elotuzumab (the active ingredient contained in Empliciti) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking elotuzumab:

More common
  • Blurred vision
  • body aches or pain
  • chest pain
  • chills
  • confusion
  • cough or hoarseness
  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
  • ear congestion
  • facial swelling
  • fever or chills
  • headache
  • hives, itching, or rash
  • hoarseness
  • irritation
  • joint pain, stiffness, or swelling
  • loss of voice
  • lower back or side pain
  • nasal congestion
  • nausea or vomiting
  • nervousness
  • painful or difficult urination
  • pounding in the ears
  • redness of the skin
  • runny nose
  • slow or fast heartbeat
  • sneezing
  • sore throat
  • sweating
  • swelling of the eyelids, face, lips, hands, or feet
  • tightness in the chest
  • troubled breathing or swallowing
  • unusual tiredness or weakness
Less common
  • Abdominal pain or tenderness
  • clay-colored stools
  • dark urine
  • loss of appetite
  • persistent sore that does not heal
  • pink skin growth
  • reddish patch or irritated area
  • shiny skin bump
  • swelling of the feet or lower legs
  • white, yellow or waxy scar-like area on the skin
  • yellow eyes or skin

Some side effects of elotuzumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common
  • Blindness
  • burning, numbness, tingling, or painful sensations
  • decreased appetite
  • decreased vision
  • decreased weight
  • diarrhea
  • difficulty having a bowel movement (stool)
  • muscle aches
  • night sweats
  • pain in the arms or legs
  • unsteadiness or awkwardness
  • weakness in the arms, hands, legs, or feet

For Healthcare Professionals

Applies to elotuzumab: intravenous powder for injection

Dermatologic

Common (1% to 10%): Night sweats[Ref]

Gastrointestinal

Very common (10% or more): Diarrhea (47%), constipation (36%), vomiting (15%), oropharyngeal pain (10%)[Ref]

Hematologic

Very common (10% or more): Lymphopenia (13%)
Frequency not reported: Leukopenia, thrombocytopenia, deep vein thrombosis[Ref]

Hepatic

Frequency not reported: Hypoalbuminemia, elevated alkaline phosphatase[Ref]

Hypersensitivity

Common (1% to 10%): Hypersensitivity
Uncommon (0.1% to 1%): Anaphylactic reaction[Ref]

Metabolic

Very common (10% or more): Decreased appetite (21%), weight loss (14%)
Frequency not reported: Hyperglycemia, hypocalcemia, low bicarbonate, hyperkalemia[Ref]

Musculoskeletal

Very common (10% or more): Pain in extremities (16%)
Common (1% to 10%): Chest pain[Ref]

Nervous system

Very common (10% or more): Peripheral neuropathy (27%), headache (15%)
Common (1% to 10%): Hypoesthesia[Ref]

Ocular

Very common (10% or more): Cataracts (12%)[Ref]

Oncologic

Common (1% to 10%): Invasive second primary malignancies (SPM)[Ref]

Other

Very common (10% or more): Fatigue (62%), pyrexia (37%)[Ref]

Psychiatric

Common (1% to 10%): Altered mood[Ref]

Renal

Common (1% to 10%): Acute renal failure[Ref]

Respiratory

Very common (10% or more): Cough (34%), nasopharyngitis (25%), upper respiratory tract infection (23%), pneumonia (20%)
Common (1% to 10%): Respiratory tract infection, pulmonary embolism[Ref]

Immunologic

Very common (10% or more): Herpes zoster[Ref]

Local

Common (1% to 10%): Infusion related reaction[Ref]

References

1. "Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb, Princeton, NJ.

2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

3. Cerner Multum, Inc. "Australian Product Information." O 0

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Hide